Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Nanobiotix

Healthcare US NBTX

35.07USD
-1.84(4.99%)

Last update at 2026-06-05T20:00:00Z

Day Range

34.6036.44
LowHigh

52 Week Range

4.8911.00
LowHigh

Fundamentals

  • Previous Close 36.91
  • Market Cap311.74M
  • Volume48466
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-23.68600M
  • Revenue TTM36.21M
  • Revenue Per Share TTM0.98
  • Gross Profit TTM 4.78M
  • Diluted EPS TTM-1.17

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -57.03300M -46.99900M -33.61400M -50.91200M -30.34500M
Minority interest - - - - -
Net income -57.04300M -47.00400M -33.62300M -50.91500M -29.89600M
Selling general administrative 17.48M 19.43M 14.27M 18.64M 12.62M
Selling and marketing expenses - - - - -
Gross profit 3.79M 0.01000M 0.05M 0.07M 0.12M
Reconciled depreciation 1.50M 1.56M 1.75M 1.77M 0.62M
Ebit -46.70200M -52.57900M -36.42800M -46.77900M -30.06700M
Ebitda -51.80200M -40.99500M -29.95300M -44.77500M -29.32800M
Depreciation and amortization -5.10000M 11.58M 6.47M 2.00M 0.74M
Non operating income net other - - - - -
Operating income -46.70200M -52.57900M -36.42800M -46.77900M -30.06700M
Other operating expenses 46.70M 47.17M 36.53M 46.85M 30.18M
Interest expense 5.84M 0.59M 0.33M 4.79M 0.85M
Tax provision 0.01000M 0.00500M 0.00900M 0.00300M 0.00000M
Interest income 0.26M 6.17M 4.68M 0.10M 1.17M
Net interest income -12.43600M 5.58M 4.44M -4.55500M -0.27700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.01000M 0.00500M 0.00900M 0.00300M -0.44900M
Total revenue 4.78M 0.01000M 0.05M 0.07M 0.12M
Total operating expenses 46.70M 47.17M 36.53M 46.85M 30.18M
Cost of revenue 0.98M - - - -
Total other income expense net -10.33100M 5.58M 2.81M -4.13300M -0.27800M
Discontinued operations - - - - -
Net income from continuing ops -57.04300M -47.00400M -33.62300M -50.91500M -30.34500M
Net income applicable to common shares -57.04100M -47.06300M -33.59000M -50.91500M -30.34500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 93.90M 59.77M 101.77M 134.03M 56.20M
Intangible assets 0.00800M 0.00100M 0.00400M 0.02M 0.16M
Earning assets - - - - -
Other current assets 0.00100M 0.00100M 9.14M 42.54M -0.00100M
Total liab 95.74M 86.81M 74.98M 63.56M 58.11M
Total stockholder equity -1.84400M -27.04500M 26.79M 70.47M -1.90900M
Deferred long term liab - - - - -
Other current liab 19.93M 12.80M 7.13M 0.00100M 0.00100M
Common stock 1.41M 1.05M 1.04M 1.03M 0.67M
Capital stock 1.41M 1.05M 1.04M 1.03M 0.67M
Retained earnings -39.70000M -57.04100M -47.00300M -33.59000M -50.91500M
Other liab - 0.27M 0.32M 0.41M 0.33M
Good will - - - - -
Other assets - -0.00100M 0.52M 0.51M 0.53M
Cash 75.28M 41.39M 83.92M 119.15M 35.09M
Cash and equivalents - - - - -
Total current liabilities 49.87M 37.94M 36.84M 19.04M 14.35M
Current deferred revenue 18.23M 16.57M 16.52M 8.59M 7.11M
Net debt -24.71800M 11.78M -37.90100M -70.17200M 9.43M
Short term debt 5.02M 4.56M 8.20M 4.87M 1.09M
Short long term debt 3.82M 3.60M 7.08M 3.67M 0.50M
Short long term debt total 50.56M 53.17M 46.02M 48.98M 44.53M
Other stockholder equity 312.51M 255.53M 255.56M 255.54M 152.97M
Property plant equipment - 7.12M 8.19M 8.26M 9.39M
Total current assets 87.34M 52.36M 93.06M 125.25M 46.13M
Long term investments 0.00000M 0.00000M 0.10M 0.10M 0.13M
Net tangible assets - -27.04600M 26.79M 70.45M -2.07100M
Short term investments - - - - -
Net receivables 9.49M 7.99M 6.93M 3.88M 8.36M
Long term debt 41.66M 44.04M 32.42M 39.12M 37.62M
Inventory 2.56M 2.98M -6.92600M -40.32000M 2.67M
Accounts payable 6.70M 4.00M 5.00M 5.57M 6.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -276.07200M -226.58200M -182.81600M -152.51400M -104.63600M
Additional paid in capital - - - - -
Common stock total equity - - - 1.03M 0.67M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 0.29M 0.42M -0.00100M -0.00100M
Deferred long term asset charges - - - - -
Non current assets total 6.56M 7.41M 8.71M 8.78M 10.08M
Capital lease obligations 5.08M 5.53M 6.52M 6.19M 6.41M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.14M -0.24200M -0.11200M -1.45900M 0.07M
Change to liabilities 2.90M 16.24M -0.99500M 2.06M 0.63M
Total cashflows from investing activities 0.14M -0.24200M -0.11200M -1.45900M 0.07M
Net borrowings -4.73500M -3.74200M 9.17M 12.43M 15.07M
Total cash from financing activities -5.65100M -5.18000M 111.77M 41.49M 14.85M
Change to operating activities -0.50500M -4.75900M 6.81M -3.49400M 0.30M
Net income -57.04100M -47.00300M -33.59000M -50.91500M -30.34500M
Change in cash -42.53300M -35.23000M 84.06M -1.10900M -11.00900M
Begin period cash flow 83.92M 119.15M 35.09M 36.20M 47.21M
End period cash flow 41.39M 83.92M 119.15M 35.09M 36.20M
Total cash from operating activities -37.10400M -29.87200M -27.53800M -41.16900M -25.98500M
Issuance of capital stock 0.00000M 0.00000M 113.66M 30.84M 0.06M
Depreciation 1.50M 1.56M 1.75M 1.77M 0.62M
Other cashflows from investing activities 0.23M -0.00900M -0.00500M -0.01500M 0.58M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - - - -
Change to account receivables -0.10100M 0.06M -0.05100M -0.08500M 0.14M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.91600M -1.43800M -1.63600M 11.14M 15.72M
Change to netincome 16.14M 4.03M -1.46300M 9.30M 2.66M
Capital expenditures 0.09M 0.23M 0.11M 1.44M 0.51M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.30M 11.54M 0.07M -1.52200M 1.08M
Stock based compensation 3.17M 3.20M 2.92M 4.32M 1.87M
Other non cash items 12.96M 0.68M -4.34100M 3.08M 0.80M
Free cash flow -37.19700M -30.10500M -27.64500M -42.61300M -26.49100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NBTX
Nanobiotix		 -1.84 4.99% 35.07 - 48.31 42.64 65.02 8474.98 -5.9485
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix

60 rue de Wattignies, Paris, France, 75012

Key Executives

Name Title Year Born
Mr. Laurent Levy Ph.D. Co-Founder, Pres of the Exec. Board & CEO 1973
Mr. Bart Van Rhijn CFO & Member of Exec. Board NA
Ms. Anne-Juliette Hermant M.A. Chief People Officer & Member of Exec. Board 1974
Prof. Para Prasad Ph.D. Co-Founder and Member of Scientific Board 1945
Mr. Earl J. Bergey Ph.d. Co-Founder 1955
Mr. Alain Dostie Chief Operating Officer NA
Ms. Kathryn M. McNeil Sr. VP of Investor Relations 1975
Mr. Brandon Owens VP of Strategic Marketing & Corp. Communication NA
Ms. Elsa Borghi Head of Innovation & Drug Discovery NA
Ms. Sarah Gaubert Head of Communication & Public Affairs Department NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions